Treatment Of melasma with Unani drug
Phase 2
Not yet recruiting
- Conditions
- Health Condition 1: L811- Chloasma
- Registration Number
- CTRI/2022/07/044080
- Lead Sponsor
- uqman Unani Medical College Hospital and Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Clinically diagnosed patients of bilateral facial Kalaf
Epidermal and mixed melasma
Exclusion Criteria
Pregnant or lactating women
Patients with history or presence of any skin allergy or allergy to hydroquinone
Patients with history or presence of any serious disease including immunological conditions like HIV current malignancies diabetes mellitus Hypertension etc
Patients who had used within 15 days prior to baseline any topical and systemic treatment for scalp diseases
Patient with history of chemical peels and facial laser treatment within 9 months and use of sun protector creams
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in modified Melasma Area and Severity Index (mMASI)Timepoint: baseline to end of treatment
- Secondary Outcome Measures
Name Time Method Change in Patient Global Assessment (PtGA) for melasma severity on 100mm VAS <br/ ><br>Change in Dermatology life quality index (DLQI)Timepoint: before and after treatment